Expansion into Mexico and Addition of Dosage Forms for Belviq and Belviq XR

An individual product commercialization initiative involving approval and sales rollout of the obesity drug Belviq in Mexico, and approval in the United States for Belviq XR, a once-daily formulation. The initiative was subsequently scaled back following withdrawal of U.S. approval and discontinuation of sales.